Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...
But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...
An open letter to US Secretary of State Marco Rubio signed by hundreds of high-profile HIV doctors, researchers and public ...
Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback